| Previous Close | 6.77 |
| Open | 6.80 |
| Volume | 992,826 |
| Avg. Volume (3M) | 843,560 |
| Market Cap | 358,501,472 |
| Price / Book | 2.70 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -4.07 |
| Total Debt/Equity (MRQ) | 0.08% |
| Current Ratio (MRQ) | 7.75 |
| Operating Cash Flow (TTM) | -101.30 M |
| Levered Free Cash Flow (TTM) | -57.88 M |
| Return on Assets (TTM) | -31.92% |
| Return on Equity (TTM) | -42.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cybin Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.0 |
| Average | 0.38 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 207.96% |
| % Held by Institutions | 42.41% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |